-

04:18:51 AM

CGEM Stock News

CGEM - Cullinan Oncology Inc

05/25/23 5:00 PM

Nasdaq : CGEM

conferencesclinical triallow float

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy Initial data indicate an acceptable safety profile of CLN-619 across all doses assessed Based on observed clinical activity in gynecological

RHEA-AI

neutral

05/11/23 4:01 PM

Nasdaq : CGEM

earningslow float

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

Zipalertinib pivotal trial now enrolling at the 100mg BID dose only First clinical data for CLN-049 and CLN-619 to be reported at EHA 2023 Congress and ASCO 2023 Annual Meeting, respectively Cash and investment position of $503.5 million as of March 31, 2023 continues to give runway into 2026

RHEA-AI

neutral

04/26/23 10:08 AM

Nasdaq : CGEM

conferencesclinical triallow float

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced

RHEA-AI

neutral

04/20/23 7:00 AM

Nasdaq : CGEM

conferenceslow float

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in

RHEA-AI

neutral

03/27/23 7:00 AM

Nasdaq : CGEM

low float

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application

RHEA-AI

neutral

03/14/23 4:35 PM

Nasdaq : CGEM

conferencesclinical triallow float

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023. CLN-617 is a cytokine therapy combining IL-2 and IL-12 in a single

RHEA-AI

neutral

03/09/23 7:00 AM

Nasdaq : CGEM

earningslow float

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Expanded clinical stage portfolio through licensing of U.S. rights to CLN-418 Received FDA clearance of IND application for CLN-978; submitted IND application for CLN-617 Initial clinical data updates for CLN-049 and CLN-619 on track for mid-2023 Potential for 6 clinical stage programs by year end

RHEA-AI

neutral

02/27/23 8:00 AM

Nasdaq : CGEM

conferenceslow float

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at

RHEA-AI

neutral

02/13/23 7:00 PM

Nasdaq : CGEM

low float

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Oncology has entered into an exclusive license with Harbour BioMed for the development and commercial rights of HBM7008 (CLN-418) in the U.S.

RHEA-AI

very positive

02/02/23 4:01 PM

Nasdaq : CGEM

conferenceslow float

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will participate in

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

CGEM Data

IndustryResearch and Development in Biotechnology
Websitewww.cullinanoncology.com
CeoNadim Ahmed
Security nameCullinan Oncology Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees62
Tags
- Other Consumer Services
- Consumer Services
AddressOne Main Street
Address2Suite 1350
StateMA
CityCambridge
Zip02142
CountryUS
Phone6174104650

About Cullinan Oncology Inc

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.